| ObjectiveDiabetic nephropathy(DKD)incidence was increasing year by year and become second only to glomerulonephritis caused by end stage renal disease second reason DPP4 is a serine protease that plays a physiological role mainly by selective cleavage of the N-terminal dipeptide residues of glucagon-like peptide-1(GLP-1).DPP-IV inhibitors delay the progression of DKD by reducing GLP-1 degradation.DPP-IV inhibitor can reduce the degradation of glucagon-like peptide-1(GLP-1),improve the body's hyperglycemia,so that the progress of diabetic nephropathy is delayed.In addition,DPP-IV inhibitors play a role in other substrates associated with diabetic nephropathy,such as expression of BNP,CRP,HCY,etc.Irisin can promote the white fat into a metabolic characteristics of brown fat,which play a role in improve insulin resistance and other biological effects.The aim of this study was to explore the mechanism of the effect of DPP-IV inhibitor lidelline on diabetic nephropathy and irisin,and to provide a new idea for the treatment of DKD.MethodsChoose 80 healthy male Wistar rats were randomly divided into normal control group NC(n=20)and diabetes nephropathy group(DN,n=60).With high glucose,high fat diet and intraperitoneal injection of STZ(25mg/kg),DN rat model was established.After building,the rats in the experimental group were randomly divided into three groups: group DN(n=18),group DN-M(n=19)and group DN-L(n=19).The DN-M group and DN-L group were treated with metformin(200mg/kg·d)and risedrine(300mg/kg·d).Finally,group NC(n=20),DN(n=18),group DN-M(n=19),group DNL(n=19)were included in the experiment.Respectively,the changes of body weight,kidney weight,biochemical indexes and serum factor irisin,and blood flow parameters were measured.And take the left side of the kidney to do HE staining,in the light microscope to observe the pathological changes of renal tissue.Study on the Biological Effects of DPP-IV Inhibitors by SPSS19.0 Statistical Software.Result1.BW: The DN-L group was significantly lower than the model group(P<0.05);KW: DN-L was group significantly lower than the normal group(P<0.05);KI: The DN-L group was significantly higher than the model group(P<0.01).2.FPG,FINS and HOMA-IR: The DN-L group was significantly lower than the model group(P<0.01);HOMA-IS: The DN-L group was significantly higher than the model group(P<0.01).3.BUN,SCR: The DN-L group was significantly lower than the model group(P<0.01).4.TC and TG: The DN-L group was significantly lower than the model group(P<0.05);HDL: The DN-L group was significantly higher than the model group(P<0.01);LDL: The DN-L group was significantly lower than the model group(P<0.05).5.PS,ED: The DN-L group was significantly higher than the model group(P<0.01);RI and PI: The DN-L group was significantly lower than the model group(P<0.01).6.Irisin: The DN-L group was significantly higher than the model group(P<0.01);Irisin has positive correlation with KE,KI,HOMA-IS,HDL,PS and ED(P<0.05)and negative with BW,FBG,FINS,HOMA-IR,BUN,SCR,TC,TG,LDL,R,PI(P<0.01).7.HE staining results: DN group renal cortex mild atrophy thinning,most of the glomerular to moderate atrophy;compared with the DN group,DN-M Group,DN-L group decreased renal cortical atrophy,glomerular light to moderate atrophy decreased.Conclusions1.DPP-IV inhibitor lidelline can reduce BW,FPG,FINS,HOMA-IR,BUN,SCR,TC,TG,LDL,RI and PI and increase the level of KI,HOMA-IS,HDL,PS,ED and irisin,to reduces renal pathological damage,thereby delaying DN progression and protecting the kidneys.2.Irisin was positively correlated with KW,KI,HOMA-IS,HDL,PS and ED and negatively correlated with BW,FPG,FINS,HOMA-IR,BUN,SCR,TC,TG,LDL,RI and PI,which made irisin a new target for the prevention and treatment of chronic metabolic diseases,and the assessment indicators of the severity of DN disease. |
PDF Full Text Request